Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in February 2001, Novacea is a privately-held, biopharmaceutical company committed to creating a world-class drug development and commercialisation organisation that addresses significant unmet medical needs. The company's first product to enter the clinic is DN-101. With DN-101, Novacea has applied its development expertise to create a novel formulation, dose and method of administration of calcitriol in order to treat various cancers.